Terms: = Pancreatic cancer AND XPO1, DKFZp686B1823, 7514, ENSG00000082898, O14980, CRM1
18 results:
1. Molecular analysis of xpo1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model.
Uddin MH; Al-Hallak MN; Khan HY; Aboukameel A; Li Y; Bannoura SF; Dyson G; Kim S; Mzannar Y; Azar I; Odisho T; Mohamed A; Landesman Y; Kim S; Beydoun R; Mohammad RM; Philip PA; Shields AF; Azmi AS
Clin Transl Med; 2023 Dec; 13(12):e1513. PubMed ID: 38131168
[TBL] [Abstract] [Full Text] [Related]
2. Inhibition of xpo1 impairs cholangiocarcinoma cell proliferation by triggering p53 intranuclear accumulation.
Zhao C; Ma B; Yang ZY; Li O; Liu SL; Pan LJ; Gong W; Dong P; Shu YJ
Cancer Med; 2023 Mar; 12(5):5751-5763. PubMed ID: 36200270
[TBL] [Abstract] [Full Text] [Related]
3. Chromosome Region Maintenance 1 (xpo1/crm1) as an Anticancer Target and Discovery of Its Inhibitor.
Liu S; Qiao W; Sun Q; Luo Y
J Med Chem; 2021 Nov; 64(21):15534-15548. PubMed ID: 34669417
[TBL] [Abstract] [Full Text] [Related]
4. Novel 2'-alkoxymethyl substituted klavuzon derivatives as inhibitors of Topo I and crm1.
Çetinkaya H; Yıldız MS; Kutluer M; Alkan A; Ozan Otaş H; Çağır A
Bioorg Chem; 2020 Oct; 103():104162. PubMed ID: 32890988
[TBL] [Abstract] [Full Text] [Related]
5. Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of pancreatic Ductal Adenocarcinoma.
Azmi AS; Khan HY; Muqbil I; Aboukameel A; Neggers JE; Daelemans D; Mahipal A; Dyson G; Kamgar M; Al-Hallak MN; Tesfaye A; Kim S; Shidham V; M Mohammad R; Philip PA
Clin Cancer Res; 2020 Mar; 26(6):1338-1348. PubMed ID: 31831564
[TBL] [Abstract] [Full Text] [Related]
6. Sumoylation in p27kip1 via RanBP2 promotes cancer cell growth in cholangiocarcinoma cell line QBC939.
Yang J; Liu Y; Wang B; Lan H; Liu Y; Chen F; Zhang J; Luo J
BMC Mol Biol; 2017 Sep; 18(1):23. PubMed ID: 28882106
[TBL] [Abstract] [Full Text] [Related]
7. crm1 inhibitory and antiproliferative activities of novel 4'-alkyl substituted klavuzon derivatives.
Kanbur T; Kara M; Kutluer M; Şen A; Delman M; Alkan A; Otaş HO; Akçok İ; Çağır A
Bioorg Med Chem; 2017 Aug; 25(16):4444-4451. PubMed ID: 28689976
[TBL] [Abstract] [Full Text] [Related]
8. First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors.
Vivaldi C; Caparello C; Musettini G; Pasquini G; Catanese S; Fornaro L; Lencioni M; Falcone A; Vasile E
Int J Cancer; 2016 Aug; 139(4):938-45. PubMed ID: 27038273
[TBL] [Abstract] [Full Text] [Related]
9. Keratin-17 Promotes p27KIP1 Nuclear Export and Degradation and Offers Potential Prognostic Utility.
Escobar-Hoyos LF; Shah R; Roa-Peña L; Vanner EA; Najafian N; Banach A; Nielsen E; Al-Khalil R; Akalin A; Talmage D; Shroyer KR
Cancer Res; 2015 Sep; 75(17):3650-62. PubMed ID: 26109559
[TBL] [Abstract] [Full Text] [Related]
10. Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human pancreatic cancer.
Kazim S; Malafa MP; Coppola D; Husain K; Zibadi S; Kashyap T; Crochiere M; Landesman Y; Rashal T; Sullivan DM; Mahipal A
Mol Cancer Ther; 2015 Jul; 14(7):1570-81. PubMed ID: 25934708
[TBL] [Abstract] [Full Text] [Related]
11. Nucleo-cytoplasmic transport as a therapeutic target of cancer.
Gravina GL; Senapedis W; McCauley D; Baloglu E; Shacham S; Festuccia C
J Hematol Oncol; 2014 Dec; 7():85. PubMed ID: 25476752
[TBL] [Abstract] [Full Text] [Related]
12. Nuclear FAM21 participates in NF-κB-dependent gene regulation in pancreatic cancer cells.
Deng ZH; Gomez TS; Osborne DG; Phillips-Krawczak CA; Zhang JS; Billadeau DD
J Cell Sci; 2015 Jan; 128(2):373-84. PubMed ID: 25431135
[TBL] [Abstract] [Full Text] [Related]
13. Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer.
Gao J; Azmi AS; Aboukameel A; Kauffman M; Shacham S; Abou-Samra AB; Mohammad RM
Oncotarget; 2014 Jun; 5(11):3444-54. PubMed ID: 24899509
[TBL] [Abstract] [Full Text] [Related]
14. Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice.
Azmi AS; Aboukameel A; Bao B; Sarkar FH; Philip PA; Kauffman M; Shacham S; Mohammad RM
Gastroenterology; 2013 Feb; 144(2):447-456. PubMed ID: 23089203
[TBL] [Abstract] [Full Text] [Related]
15. Targeting the nuclear transport machinery by rational drug design.
Mao L; Yang Y
Curr Pharm Des; 2013; 19(12):2318-25. PubMed ID: 23082981
[TBL] [Abstract] [Full Text] [Related]
16. Nuclear export of proteins and drug resistance in cancer.
Turner JG; Dawson J; Sullivan DM
Biochem Pharmacol; 2012 Apr; 83(8):1021-32. PubMed ID: 22209898
[TBL] [Abstract] [Full Text] [Related]
17. Prognostic value of crm1 in pancreas cancer.
Huang WY; Yue L; Qiu WS; Wang LW; Zhou XH; Sun YJ
Clin Invest Med; 2009 Dec; 32(6):E315. PubMed ID: 20003838
[TBL] [Abstract] [Full Text] [Related]
18. Nuclear annexin II negatively regulates growth of LNCaP cells and substitution of ser 11 and 25 to glu prevents nucleo-cytoplasmic shuttling of annexin II.
Liu J; Rothermund CA; Ayala-Sanmartin J; Vishwanatha JK
BMC Biochem; 2003 Sep; 4():10. PubMed ID: 12962548
[TBL] [Abstract] [Full Text] [Related]
